Company Overview
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Why Investors Should Care
Revenue has grown at a 23.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $88.50M (+24.1% YoY); net profit $-35.27M.
- Trailing 12 Months Year-on-year growth — revenue +34.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 23.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 23.83% |
| 1 Year: | 34.20% |
Stock Price Performance
| 1 Year: | +246.74% |
| 6 Months: | +37.27% |
| 3 Months: | +78.13% |
| 1 Month: | +13.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.03 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 23.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BDSX Biodesix, Inc. PHARMA | 26.63 | -8.59 | $280.98M | 0.00% | -39.80% | - | 23.83% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 3.94M | 5.10M | 4.24M | 9.19M | 28.87M | 11.88M | 6.53M | 6.55M | 10.95M | 11.11M | 9.06M | 11.87M | 13.49M | 14.82M | 17.93M | 18.15M | 17.96M | 20.02M | 21.77M | 25.55M | 26.86M |
| Operating Income | - | - | -9.03M | -8.42M | -5.62M | -6.24M | -5.58M | -10.59M | -13.09M | -14.46M | -11.63M | -10.61M | -16.37M | -10.93M | -7.17M | -11.02M | -8.24M | -8.59M | -9.14M | -9.72M | -7.05M | -6.20M | -5.39M |
| Net Income | -7.74M | -6.86M | -9.60M | -9.71M | -8.27M | -8.85M | -6.96M | -11.40M | -11.51M | -15.59M | -15.82M | -13.70M | -18.70M | -13.36M | -10.95M | -13.61M | -10.81M | -10.26M | -11.10M | -11.47M | -8.72M | -7.79M | -7.27M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.41 | -0.50 | -0.40 | -0.34 | -0.24 | -0.17 | -0.14 | -0.14 | -0.08 | -1.40 | -1.52 | -0.08 | -1.16 | -0.81 | -0.71 |
| R&D Expense | - | - | 2.36M | 2.90M | 2.11M | 2.71M | 3.32M | 3.32M | 3.29M | 3.21M | 3.36M | 2.97M | 3.25M | 2.91M | 1.94M | 2.04M | 2.56M | 2.55M | 2.87M | 3.27M | 2.99M | 3.29M | 3.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 24.55M | 45.56M | 54.51M | 38.21M | 49.09M | 71.32M | 88.50M |
| Operating Income | -26.74M | -22.93M | -40.94M | -50.59M | -41.34M | -34.50M | -27.87M |
| Net Income | -30.73M | -65.45M | -43.16M | -65.45M | -52.15M | -42.93M | -35.27M |
| Diluted EPS | - | - | -1.58 | -1.55 | -0.64 | -6.64 | -4.67 |
| R&D Expense | 10.47M | 10.82M | 12.79M | 13.10M | 9.99M | 9.56M | 12.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 45.03M | 121.07M | 76.10M | 92.91M | 99.10M | 97.24M | 87.48M |
| Current Assets | - | - | - | - | 53.33M | 39.68M | 39.48M | 32.52M |
| Cash & Equivalents | - | 5.29M | 62.13M | 32.71M | 43.09M | 26.28M | 26.25M | 18.99M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 5.07M | 7.68M | 8.60M | 9.04M |
| Total Liabilities | - | 76.21M | 79.90M | 56.37M | 72.30M | 94.52M | 76.37M | 89.94M |
| Current Liabilities | - | 22.60M | 32.12M | 28.96M | 22.84M | 33.42M | 14.32M | 17.44M |
| Long Term Debt | - | - | 28.08M | 10.07M | 25.00M | 35.23M | 36.41M | 47.45M |
| Total Debt | - | - | - | - | 31.85M | 60.69M | 61.98M | 72.85M |
| Total Equity | -194.63M | -225.14M | 41.17M | 19.73M | 20.61M | 4.58M | 20.88M | -2.46M |
| Shares Outstanding | - | - | - | - | 3.88M | 4.81M | 7.27M | 8.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.73M | -21.37M | -28.22M | -44.97M | -22.87M | -48.65M | -23.27M |
| Investing Cash Flow | -1.87M | -2.93M | -2.55M | -3.53M | -23.06M | -3.44M | -403.00K |
| Financing Cash Flow | 22.97M | 81.13M | 1.26M | 58.88M | 29.13M | 52.05M | 16.42M |
| Capital Expenditure | -1.31M | -1.95M | -2.24M | -3.30M | -22.92M | -3.23M | -259.00K |
| Free Cash Flow | -23.04M | -23.31M | -30.46M | -48.27M | -45.79M | -51.88M | -23.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -108.9% | -50.3% | -75.1% | -132.4% | -84.2% | -48.4% | -31.5% |
| Net Margin % | -125.1% | -143.7% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
| ROE % | 13.6% | -159.0% | -218.8% | -317.6% | -1,138.6% | -205.6% | 1,430.6% |
| ROCE % | -119.2% | -25.8% | -86.9% | -72.2% | -62.9% | -41.6% | -39.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AIGH Capital Management LLC | 6.43% | 678.33K | $19.81M |
| 2 | Soleus Capital Management, L.P. | 5.55% | 585.96K | $17.11M |
| 3 | Telemark Asset Management, LLC | 4.64% | 489.82K | $14.30M |
| 4 | Aberdeen Group plc | 3.68% | 388.64K | $11.35M |
| 5 | Birchview Capital, LP | 2.72% | 286.80K | $8.37M |
| 6 | Vanguard Capital Management LLC | 2.69% | 284.17K | $8.30M |
| 7 | Essex Investment Management Co LLC | 2.29% | 241.91K | $7.06M |
| 8 | Opaleye Management Inc. | 1.71% | 180.00K | $5.26M |
| 9 | Marshall Wace LLP | 1.10% | 116.20K | $3.39M |
| 10 | Perceptive Advisors Llc | 1.03% | 108.69K | $3.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDSX
Biodesix Stock Price Forecast. Should You Buy BDSX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5nZGE4a3ExNmt4YnBacVhoWlJzSWpUZFhtc3IydUVaTTNESzMzdllmd3hxc0ZBZ3dVMGVEQ0lzcmk5WDlBaHc3Tw?oc=5" target="_blank">Biodesix Stock Price Forecast. Should You Buy BDSX?</a> <f…
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNaFIwMFl1Smo3WHRlMVc2THN6VXlOcHAzTG55YzZ5UDdRYXFBM1AybC1SMFp5X0FFTVdRaTFrWWlNSHJ1TVgtejFBREJSdW1VUXJZV3NxRmdOUWpkNTd6XzlIdnhGdzduSmRTaVhFWDVJM1dRNndNUEw3MS0tRDh1MUVmUlFSRTgwWmFFZz…
BlackRock Inc. Invests $970,000 in Biodesix, Inc. $BDSX - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNTUQwMHdkOGM5MjJlbm14QWo2V3d3WHVTNmc5TDRzTS1NU3pGUEpRU3QyWWhtS0F4RFlMY2l4aUhlS0hsX0pmS01XT0dsS1FyOEEyRlo4RGUzSk92T0RaYjNXckI5YkhzUlRIUlctT2tPeTRORFdWcnVGaVFuTEVZRjJRRGNIdVlVT1FTOT…
(BDSX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNU1QzSUtXcy15T0hlV3phV0ZFdk5xb1lsb2FqRmJCMEROaHdpWnZVZTd0RzJPZU1mOTJuVFgtS1ljbkR1RVpiY1VsaXpRNzd4Z05Xd0wyOTU4OTYyclhneWtNbWJsTGQ1OTJfY3pLd29TNHluOS14dWIzVjhzMENJdVNubkxrTEwwZFJ3am…
BioDesix (NASDAQ:BDSX) Passes Minervini Trend Template but Setup Quality Remains Weak - ChartMill
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQZXgtNDRfLWxTWHdWc0RyZllSdE9lYnhrSjhOYVlPS0NaMUhrQVlETGE5RXF6N3YydTNxenZuV3pkb2VNT05vNmdtYnlwME5uazJnOVZWaUhLTVNRU3RFTlEzR2gzWko0NzNBaU9NcjNJSk12N1lObzRMbkFYZTRlWE16d0ZQdmllYVcwOW…
$BDSX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQM29RNENLbTBCWHliYnRDNHpMcGIwRHFHM3J6UDljSnNrVXBuYkxRLXNkVkF5YkU0blFGVnoyOEtDVHVvaUtzZ3BjOE9QNEFyUjFqR3VwREttQ2x5T2twbGtfX1g0MFJvZkJIbVdUM0stOVZ3ay1yN1oxNHJRV2pfc21tblpWU05fdDM5eT…
BDSX — Frequently Asked Questions
What is the current share price of Biodesix, Inc. (BDSX)?
As of 2026-09-19 21:16 PDT, Biodesix, Inc. (BDSX) trades at $26.63 on NasdaqGM. Its 52-week range is $5.46 to $30.60.
What is the market capitalisation of BDSX?
Biodesix, Inc. (BDSX) has a market capitalisation of $280.98M on NasdaqGM.
What is the P/E ratio of BDSX?
BDSX trades at a trailing price-to-earnings (P/E) ratio of -8.59. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 31.23.
Is BDSX a good stock to buy?
This page provides a data-driven analysis of Biodesix, Inc. (BDSX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.